Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Tria
ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing...
Toothpaste ingredient may bust up cystic fibrosis biofilms
A common antibacterial substance in toothpaste may combat life-threatening diseases such as cystic fibrosis when combined with an with an...
Gastrointestinal Cancers More Common in Adults with CF, Especially After Transplant, Study Finds
Patients with cystic fibrosis (CF) are at higher-than-average risk of developing gastrointestinal cancers, especially those who underwent...
Improving Antibiotic Strategies To Combat Respiratory Infections In Cystic Fibrosis Patients
Cystic fibrosis (CF) is an inherited, progressive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR)...
Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on t
Program to Pursue Broad Label for PTI-428 as an Add-On Therapy to CFTR Modulator Based Treatment BRIGHTON, Mass., May 8, 2018...
Data from Spyryx Biosciences' HOPE-1 Phase 2 Clinical Trial to be Presented in a Late-Breaking O
DURHAM, N.C., May 8, 2018 /PRNewswire/ -- Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel...